110 related articles for article (PubMed ID: 24015417)
1. [Picture in clinical hematology].
Hatsuse M; Shimazaki C; Yumiba T
Rinsho Ketsueki; 2013 Jan; 54(1):1. PubMed ID: 24015417
[No Abstract] [Full Text] [Related]
2. [Vocal cord paralysis secondary to vincristine].
Nafil H; Tazi I; Mahmal L
Rev Neurol (Paris); 2012 May; 168(5):464-5. PubMed ID: 22387202
[No Abstract] [Full Text] [Related]
3. Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma.
Hosoi M; Yamamoto G; Imai Y; Kurokawa M
Ann Hematol; 2010 Feb; 89(2):207-8. PubMed ID: 19582454
[No Abstract] [Full Text] [Related]
4. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
Furman RR; Martin P; Ruan J; Cheung YK; Vose JM; LaCasce AS; Elstrom R; Coleman M; Leonard JP
Cancer; 2010 Dec; 116(23):5432-9. PubMed ID: 20665890
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphism at
Bashash M; Connors JM; Gascoyne RD; Meissner B; Schuetz JM; Leach S; Slack GW; Berry BR; Hu H; Sehn LH; Brooks-Wilson AR; Spinelli JJ
Haematologica; 2017 May; 102(5):e199-e202. PubMed ID: 28154089
[No Abstract] [Full Text] [Related]
7. Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria.
Rashidi A; Oak E; Carson KR; Wagner-Johnston ND; Kreisel F; Bartlett NL
Leuk Lymphoma; 2016 May; 57(5):1191-3. PubMed ID: 26397936
[No Abstract] [Full Text] [Related]
8. Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas: the SEXIE-R-CHOP-14 trial of the DSHNHL.
Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):8-9. PubMed ID: 25768993
[No Abstract] [Full Text] [Related]
9. MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R.
Lai C; Roschewski M; Melani C; Pittaluga S; Shovlin M; Steinberg SM; Dunleavy K; Pack S; Jaffe ES; Wilson WH
Leuk Lymphoma; 2018 Feb; 59(2):505-508. PubMed ID: 28641474
[No Abstract] [Full Text] [Related]
10. [A case of neurotoxicity reduced with pregabalin in R-CHOP chemotherapy for diffuse large B-cell lymphoma].
Nakashima T; Kiba T; Ogawa Y; Kimura A; Kido M; Okikawa Y; Ito T; Saito A; Hosokawa A; Shintani H; Okada Y; Taniguchi T; Taniyama K; Kozawa K; Niimi H
Gan To Kagaku Ryoho; 2012 May; 39(5):809-12. PubMed ID: 22584337
[TBL] [Abstract][Full Text] [Related]
11. CHOP chemotherapy as standard therapy for treatment of patients with diffuse histiocytic lymphoma.
Fisher RI
Important Adv Oncol; 1990; ():217-25. PubMed ID: 2182520
[No Abstract] [Full Text] [Related]
12. CHOP plus rituximab--balancing facts and opinion.
Cheson BD
N Engl J Med; 2002 Jan; 346(4):280-2. PubMed ID: 11807154
[No Abstract] [Full Text] [Related]
13. DLBCL developed into fatal liver failure during rituximab-containing chemotherapy.
Shimazu Y; Nohgawa M
J Clin Exp Hematop; 2019; 59(2):93-95. PubMed ID: 31257349
[No Abstract] [Full Text] [Related]
14. The clinician's decision of whether CHOP chemotherapy should be standard therapy for treatment of patients with diffuse histiocytic lymphoma.
Connors JM
Important Adv Oncol; 1990; ():227-33. PubMed ID: 2182521
[No Abstract] [Full Text] [Related]
15. [Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up].
Cheng ZX; Zou SH; Li F; Li JM; Wang JM; Chen FY; Cao JN; Wang C; Wei Z; Cheng YF
Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):257-60. PubMed ID: 22781712
[TBL] [Abstract][Full Text] [Related]
16. Lymphomatous pericardial effusion positive for Mycobacterium tuberculosis by PCR analysis.
Michelis FV; Petrogiannopoulos CL; Papamichael KX; Kostakos ND; Kiagia EZ; Deliousis A; Zacharof AK
Int J Infect Dis; 2008 Sep; 12(5):564-5. PubMed ID: 18406651
[No Abstract] [Full Text] [Related]
17. Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis.
Lee L; Crump M; Khor S; Hoch JS; Luo J; Bremner K; Krahn M; Hodgson DC
Br J Haematol; 2012 Aug; 158(4):481-8. PubMed ID: 22671571
[TBL] [Abstract][Full Text] [Related]
18. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.
Gordon LI; Harrington D; Andersen J; Colgan J; Glick J; Neiman R; Mann R; Resnick GD; Barcos M; Gottlieb A
N Engl J Med; 1992 Nov; 327(19):1342-9. PubMed ID: 1383819
[TBL] [Abstract][Full Text] [Related]
19. Molecular analysis of a CD19-negative diffuse large B-cell lymphoma.
Delage L; Manzoni D; Quinquenet C; Fontaine J; Maarek A; Chabane K; Mosnier I; Hayette S; Callet-Bauchu E; Grange B; Plesa A; Sujobert P
Haematologica; 2019 Mar; 104(3):e114-e116. PubMed ID: 30545922
[No Abstract] [Full Text] [Related]
20. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma.
Oki Y; Younes A; Copeland A; Hagemeister F; Fayad LE; McLaughlin P; Shah J; Fowler N; Romaguera J; Kwak LW; Pro B
Br J Haematol; 2013 Jul; 162(1):138-41. PubMed ID: 23590726
[No Abstract] [Full Text] [Related]
[Next] [New Search]
